NAB-PACLITAXEL
Clinical trials for NAB-PACLITAXEL explained in plain language.
Never miss a new study
Get alerted when new NAB-PACLITAXEL trials appear
Sign up with your email to follow new studies for NAB-PACLITAXEL, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
New drug cocktail aims to shrink lung tumors before surgery
Disease control Recruiting nowThis phase 2 trial tests a combination of three drugs (tislelizumab, anlotinib, and nab-paclitaxel) given before surgery to people with stage III non-small cell lung cancer. The goal is to see if this approach can eliminate or greatly reduce the tumor before it is removed. The st…
Matched conditions: NAB-PACLITAXEL
Phase: PHASE2 • Sponsor: Qilu Hospital of Shandong University • Aim: Disease control
Last updated Jun 27, 2026 14:00 UTC
-
New drug combo aims to save kidneys in pelvic cancer patients
Disease control Recruiting nowThis phase II trial tests whether a combination of tislelizumab (an immunotherapy) and nab-paclitaxel (a chemotherapy drug) can treat renal pelvic cancer while allowing patients to keep their kidney. About 35 adults with early-stage cancer will receive the drugs, and if the tumor…
Matched conditions: NAB-PACLITAXEL
Phase: PHASE2 • Sponsor: Tianjin Medical University Second Hospital • Aim: Disease control
Last updated Jun 27, 2026 07:57 UTC
-
New trial tests which chemo combo best shrinks tough breast tumors
Disease control Recruiting nowThis phase 2 trial compares two chemotherapy combinations given before surgery for triple-negative breast cancer. About 520 women will receive either nab-paclitaxel plus carboplatin or nab-paclitaxel plus epirubicin. The goal is to see which combo better eliminates cancer cells i…
Matched conditions: NAB-PACLITAXEL
Phase: PHASE2 • Sponsor: Hebei Medical University Fourth Hospital • Aim: Disease control
Last updated Jun 26, 2026 16:12 UTC
-
New hope for aggressive breast cancer: two chemo cocktails face off in clinical trial
Disease control Recruiting nowThis Phase 2 trial is testing two different chemotherapy combinations in 414 women with advanced triple-negative breast cancer (TNBC), a fast-growing type that lacks common treatment targets. One group gets nab-paclitaxel plus carboplatin, the other gets nab-paclitaxel plus capec…
Matched conditions: NAB-PACLITAXEL
Phase: PHASE2 • Sponsor: Hebei Medical University Fourth Hospital • Aim: Disease control
Last updated Jun 26, 2026 15:49 UTC